Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2021 08:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience to Present at the KCSA Cannabis Investor Conference

San Diego, Calif, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a biopharmaceutical company focused on developing differentiated, proprietary...
December 16, 2020 08:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience Reports that Superior Reduction of Intraocular Pressure of its Unique Nanoemulsion Formulation of THCVHS is Published in Peer-Reviewed Journal

Drug Delivery and Translational Research article highlights significantly better drug load and duration of activity of prodrug of THC compared to leading commercial drugs for treating glaucoma San...
December 07, 2020 08:45 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience to Present at the Benzinga Global Small Cap Virtual Conference

San Diego, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on developing...
September 30, 2020 08:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience Provides Corporate Update

Renewed team and capital focused on advancing lead compound for glaucoma into human studies Ongoing development of lead compound, THCVHS, includes near-term preclinical assessments of neuroprotection...
September 03, 2020 11:39 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

San Diego, CA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI a preclinical-stage biopharmaceutical company focused on the development of proprietary first-in-class...
August 13, 2020 08:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience Appoints Biotech Veteran Dr. Margaret Dalesandro to Board of Directors

San Diego, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on the development of...
August 10, 2020 08:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience Appoints Biotech Executive Punit Dhillon as CEO

Renewed team and capital focused on advancing lead compound for glaucoma into clinical development San Diego, Calif, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI)...
August 04, 2020 18:32 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience Raises approximately $7.0 Million in Upsized Registered Offering

Long Beach, CA, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address...
July 31, 2020 09:20 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience Announces Pricing of $7.0 Million Upsized Registered Offering

Long Beach, CA, July 31, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address...
June 09, 2020 09:37 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience Announces Presentation of Cannabidiol-Valine-Hemisuccinate Ocular Data at Virtual ARVO® Meeting

Bio-engineered analog of CBD (CBDVHS) exhibited highly significant potency when compared to CBD in lowering biomarkers associated with inflammation and fibrosis in a validated human tissue model of...